✦ LIBER ✦

Duration of vitamin K antagonist therapy for venous thromboembolism: A systematic review of the literature

✍ Scribed by Michael B. Streiff; Jodi B. Segal; Leonardo J. Tamariz; Mollie W. Jenckes; Dennis T. Bolger; John Eng; Jerry A. Krishnan; Eric B. Bass

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 345 KB
Volume: 81
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.20691

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The risk of venous thromboembolic diseas

The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma : A systematic review

✍ Steven R. Deitcher; Marcelo P. V. Gomes 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

## Background: Tamoxifen therapy for patients with breast carcinoma is perceived as an independent risk factor for venous thromboembolic events (vte), but the risk associated with other adjuvant therapies is less well recognized. ## Methods: The authors conducted a computerized pubmed literature

Anticoagulation for the initial treatmen

Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer : A systematic review

✍ Elie A. Akl; Sandeep Rohilla; Maddalena Barba; Francesca Sperati; Irene Terrenat 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 312 KB 👁 1 views

## Abstract ## BACKGROUND. The authors compared the relative efficacy and safety of low‐ molecular‐weight heparin (LMWH) and unfractionated heparin (UFH) for the initial treatment of venous thromboembolism (VTE) between patients with and without cancer. ## METHODS. By using Cochrane methodology

Susac's syndrome: Intratympanic therapy

Susac's syndrome: Intratympanic therapy for hearing loss and a review of the literature

✍ Brianna K. Crawley; Abby Close; Cecilia Canto; Jeffrey P. Harris 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

## Abstract Two cases of Susac's Syndrome are presented with a discussion of treatment modalities for the associated severe sensorineural deafness. Patients were managed with high dose oral steroids, anticoagulants and immunosuppressive drugs. The addition of intratympanic methylprednisolone inject

Oral budesonide for the therapy of post-

Oral budesonide for the therapy of post-liver transplant de novo inflammatory bowel disease: A case series and systematic review of the literature

✍ A. Sidney Barritt IV; Steven L. Zacks; Tara C. Rubinas; Hans H. Herfarth 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 442 KB 👁 2 views

## Background: The therapy for posttransplant ibd is clinically challenging. patients receiving liver transplants are immunosuppressed to prevent rejection, but via an unknown mechanism develop de novo ibd in spite of receiving some of the same medications used for therapy in traditional ibd. in th

Patient selection, cancer control, and c

Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure : A systematic review of the literature

✍ Paul L. Nguyen; Anthony V. D'Amico; Andrew K. Lee; W. Warren Suh 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB 👁 1 views

## Abstract Among men who experience prostate‐specific antigen (PSA) failure after external beam radiation or brachytherapy (RT), many will harbor occult micrometastases; however, a significant minority will have a true local‐only failure and, thus, potentially may benefit from a salvage local ther

Rituximab therapy for thrombotic thrombo

Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders

✍ James N. George; Robert D. Woodson; Joseph E. Kiss; Kiarash Kojouri; Sara K. Ves 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

## Abstract The rationale for immunosuppressive therapy of thrombotic thrombocytopenic purpura (TTP) was established by observations that TTP may be caused by autoantibodies to ADAMTS13. Patients with high‐titer autoantibodies to ADAMTS13 may have a higher mortality, and survivors may require prolo